Exscientia opens new office in Oxford as part of plan for rapid growth and expansion

IMG_5882.jpg

Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce the opening of its new offices in central Oxford, UK, in the UK’s most dynamic life science cluster.

In response to the Company’s rapid growth over the last 12 months, Exscientia’s new offices, in the heart of Oxford’s St. Giles’ area, will provide international clients and collaborators with excellent access to Company. In addition, its close proximity to leading academic research institutions in Oxford University will enable opportunities for new collaborations to be fostered. This development is in parallel with the planned expansion of Exscientia’s Dundee offices, another of the UK’s leading scientific centres of excellence.

Andrew Hopkins, CEO of Exscientia, said: “Opening an Oxford office allows us to have a home at the centre of UK biotech creativity. This move comes at a key time for Exscientia, having recently announced exciting strategic partnerships with GSK and Sanofi and our first external investment from Evotec. Our new offices have been carefully designed to foster a creative environment for team members. The expansion of Exscientia at Oxford and Dundee is part of our plan to recruit highly talented personnel to drive our mission to improve the way new medicines are discovered by application of artificial intelligence.”

Exscientia recently won the Best Emerging Biotech Company Award at the OBN Annual Awards ceremony in Oxford.

Notes for editors About Exscientia Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

Exscientia’s innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds prioritised for synthesis by its AI systems simultaneously balance potency, selectivity and pharmacokinetic criteria in order to deliver successful experimental outcomes.

By applying a rapid design-make-test cycle, the Exscientia AI platform actively learns from the preceding experimental results and rapidly evolves compounds towards the desired candidate criteria.

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.

As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

Exscientia is collaborating with several leading pharmaceutical companies. In addition to Evotec, partners include Sanofi (metabolic disease), Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals (CNS) and GSK.

Exscientia has offices in Oxford and Dundee, UK.

For more information visit www.exscientia.co.uk or follow us on Twitter
www.twitter.com/exscientialtd

Media enquiries:

Mark Swindells - Chief Operating Officer contact@exscientia.co.uk

Mark Swallow / Pip Batty / Sylvie Berrebi – Citigate Dewe Rogerson
exscientia@citigatedewerogerson.com +44 207 638 9571